Jubilant Pharmova's Q2 FY 2025-26 Quarterly Results

Result Summary

• Jubilant Pharmova Ltd reported a 3.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.4%.
• Its expenses for the quarter were up by 1.2% QoQ and 10.2% YoY.
• The net profit increased 17.0% QoQ and increased 17.0% YoY.
• The earnings per share (EPS) of Jubilant Pharmova Ltd stood at 7.57 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Jubilant Pharmova Ltd is a well-established company operating in the pharmaceutical industry. It is primarily engaged in the development and manufacturing of pharmaceutical products and services. The company offers a variety of products, including generic formulations, specialty pharmaceuticals, and contract manufacturing services. Jubilant Pharmova is known for its focus on innovation and quality, aiming to provide affordable healthcare solutions globally. The latest information about any specific recent developments is not available from the provided data.

Revenue

For the second quarter of fiscal year 2026 (Q2FY26), Jubilant Pharmova Ltd reported a total income of ₹1,976.20 crores. This represents a quarter-over-quarter (QoQ) increase of 3.3% from the ₹1,912.70 crores reported in the first quarter of fiscal year 2026 (Q1FY26). Year-over-year (YoY), the total income increased by 11.4% from ₹1,774.00 crores in the second quarter of fiscal year 2025 (Q2FY25). The revenue growth reflects the company's performance over the analyzed period, showcasing a consistent upward trend in its income generation.

Profitability

The company's profitability metrics for Q2FY26 show a robust performance. Profit before tax (PBT) was ₹190.40 crores, a 23.2% increase QoQ from ₹154.50 crores in Q1FY26, and a 31.8% rise YoY from ₹144.50 crores in Q2FY25. After accounting for taxes, the profit after tax (PAT) stood at ₹119.90 crores, reflecting a 17.0% increase both QoQ and YoY. The earnings per share (EPS) also improved, reaching ₹7.57, up 17.0% QoQ from ₹6.47 in Q1FY26, and a 17.2% growth YoY from ₹6.46 in Q2FY25. These profitability figures provide insights into the company's financial efficiency and its ability to convert increased revenues into profits.

Operating Metrics

Jubilant Pharmova Ltd's operating metrics for the period under review indicate a careful management of expenses and tax liabilities. Total expenses in Q2FY26 were ₹1,780.00 crores, marking a 1.2% rise QoQ from ₹1,758.20 crores in Q1FY26 and a 10.2% increase YoY from ₹1,615.30 crores in Q2FY25. The tax expenditure in Q2FY26 was ₹70.40 crores, up 35.6% QoQ from ₹51.90 crores in Q1FY26 and a notable 68.0% increase YoY from ₹41.90 crores in Q2FY25. These figures highlight the company's approach to managing its operational costs and tax obligations effectively over the quarters analyzed.